73-05-2
73-05-2
Chemical Structure
Phentolamine hydrochloride
- CAS No.: 73-05-2
- Formula:C17H20ClN3O
- Molecular Weight:317.82
IUPAC Name: 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(p-tolyl)amino)phenol hydrochloride
InChIKey: TUEJFGFQYKDAPM-UHFFFAOYSA-N
SMILES: OC1=CC=CC(N(CC2=NCCN2)C3=CC=C(C)C=C3)=C1.[H]Cl
Biological Activity: Phentolamine hydrochloride is an orally active, selective α1 and α2 Adrenergic receptor antagonist. Phentolamine hydrochloride antagonizes the vasodilatory effect of Cromakalim (HY-110011) on isolated circumflex coronary artery segments in dogs. Phentolamine hydrochloride reduces systemic vascular resistance and increases cardiac output. Phentolamine hydrochloride improves erectile dysfunction. Phentolamine hydrochloride can be used for the research of erectile dysfunction[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Phentolamine hydrochloride | 99.91% | Phentolamine hydrochloride is an orally active, selective α1 and α2 Adrenergic receptor antagonist. Phentolamine hydrochloride antagonizes the vasodilatory effect of Cromakalim (HY-110011) on isolated circumflex coronary artery segments in dogs. Phentolamine hydrochloride reduces systemic vascular resistance and increases cardiac output. Phentolamine hydrochloride improves erectile dysfunction. Phentolamine hydrochloride can be used for the research of erectile dysfunction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phentolamine hydrochloride (Standard) | ≥98% | Phentolamine (hydrochloride) (Standard) is the analytical standard of Phentolamine (hydrochloride). This product is intended for research and analytical applications. Phentolamine hydrochloride is an orally active adrenergic α receptor-blocking agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phentolamine-d4 hydrochloride | Phentolamine-d4 (hydrochloride) is the deuterium labeled Phentolamine hydrochloride. Phentolamine hydrochloride is a reversible, non-selective, and orally active blocker of α1 and α2 adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance. Phentolamine hydrochloride can be used for the research of pheochromocytoma-related hypertension, heart failure and erectile dysfunction. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Naphazoline nitrate | 99.12% | Naphazoline (Naphthazoline) nitrate is an α-adrenergic receptor agonist. Naphazoline nitrate reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline nitrate reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline nitrate can be used for non-bacterial conjunctivitis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
UCM765 | UCM765 is a selective MT2-type melatonin receptor ligand with hypnotic, analgesic and anxiolytic activities. The partial agonist effect of UCM765 has attracted attention in pharmacological studies. By structurally modifying UCM765, its water solubility and metabolic stability can be improved, thereby increasing its bioavailability. The biological activity of UCM765 has been verified in a rat model, supporting its potential for further pharmacological studies. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phentolamine (Standard) | ≥98% | Phentolamine (Standard) is the analytical standard of Phentolamine. This product is intended for research and analytical applications. Phentolamine is a potent, selective and orally active α1 adrenergic and α2 adrenergic receptor antagonist. Phentolamine can be used for the research of erectile dysfunction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phentolamine mesylate (Standard) | ≥98% | Phentolamine (mesylate) (Standard) is the analytical standard of Phentolamine (mesylate). This product is intended for research and analytical applications. Phentolamine mesylate (Phentolamine methanesulfonate) is a reversible, non-selective, and orally active blocker of α1 and α2 adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance. Phentolamine mesylate can be used for the research of pheochromocytoma-related hypertension, heart failure and erectile dysfunction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Naphazoline hydrochloride (Standard) | ≥98% | Naphazoline (hydrochloride) (Standard) is the analytical standard of Naphazoline (hydrochloride). This product is intended for research and analytical applications. Naphazoline (Naphthazoline) hydrochloride is a potent α-adrenergic receptor agonist. Naphazoline hydrochloride reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline hydrochloride reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF。Naphazoline hydrochloride can be used for non-bacterial conjunctivitis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Antazoline hydrochloride | 99.60% | Antazoline hydrochloride is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline hydrochloride can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline hydrochloride can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline hydrochloride can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline hydrochloride also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline hydrochloride has anti-arrhythmic effect in acute myocardial infarctions. Antazoline hydrochloride can be studied in research for cardiovascular diseases, and HBV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Antazoline | 99.70% | Antazoline (Phenazoline) is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline has anti-arrhythmic effect in acute myocardial infarctions. Antazoline can be studied in research for cardiovascular diseases, and HBV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phentolamine Analogue 1 | Phentolamine Analogue 1 is an analogue of phentolamine. Phentolamine is a nonselective alpha-adrenergic antagonist. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phentolamine acetate | Phentolamine acetate is a compound with anti-inflammatory and anticancer activities. Phentolamine acetate has been shown to inhibit the growth of certain bacteria, including Staphylococcus aureus. Phentolamine acetate exhibits potent biological activity in vitro. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Goldstein I, et al. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction. Int J Impot Res. 2000;12 Suppl 1:S75-S80. [Content Brief]
- [2]. Majid PA, et al. Phentolamine for vasodilator treatment of severe heart-failure. Lancet. 1971 Oct 2;2(7727):719-24. [Content Brief]
- [3]. McPherson GA, et al. Phentolamine and structurally related compounds selectively antagonize the vascular actions of the K+ channel opener, cromromakalim. Br J Pharmacol. 1989;97(3):941-949. [Content Brief]
